Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-AF
2022-501419-15-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial of milvexian in Atrial fibrillation (AFib) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Composite of stroke and non-CNS systemic embolism. Planned start Aug 2023; status: authorised.
02
Drugs
milvexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-501419-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501419-15-00.